These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15179554)

  • 1. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
    Figlin RA; Alvin H; Meinhardt CL
    Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
    [No Abstract]   [Full Text] [Related]  

  • 2. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
    Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
    Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
    Panelli MC; Wang E; Marincola FM
    Clin Cancer Res; 2005 May; 11(10):3601-3. PubMed ID: 15897553
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular markers to predict response to therapy.
    Garcia-Donas J; Rodriguez-Antona C; Jonasch E
    Semin Oncol; 2013 Aug; 40(4):444-58. PubMed ID: 23972708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
    Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
    Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
    Mulders P; Bleumer I; Debruyne F; Oosterwijk E
    Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-angiogenic therapy in renal cell carcinoma.
    Sharma SG; Nanda S; Longo S
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic factors in renal cell carcinoma].
    Wen JJ; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):850-3. PubMed ID: 24507112
    [No Abstract]   [Full Text] [Related]  

  • 10. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly approved therapies for RCC and their effect on the standard of care.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
    [No Abstract]   [Full Text] [Related]  

  • 14. Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.
    Courcier J; de la Taille A; Nourieh M; Leguerney I; Lassau N; Ingels A
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive biomarkers in renal cell carcinoma.
    Vickers MM; Heng DY
    Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbonic anhydrase IX/G250/MN: a molecule too good to be true?
    Oosterwijk E
    BJU Int; 2008 Mar; 101(5):527-8. PubMed ID: 18257853
    [No Abstract]   [Full Text] [Related]  

  • 17. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
    George DJ; Kaelin WG
    N Engl J Med; 2003 Jul; 349(5):419-21. PubMed ID: 12890838
    [No Abstract]   [Full Text] [Related]  

  • 18. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
    Signoretti S; Regan M; Atkins M
    BJU Int; 2008 Jun; 101 Suppl 4():31-5. PubMed ID: 18430120
    [No Abstract]   [Full Text] [Related]  

  • 19. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
    Grabmaier K; A de Weijert MC; Verhaegh GW; Schalken JA; Oosterwijk E
    Oncogene; 2004 Jul; 23(33):5624-31. PubMed ID: 15184875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.